NDAORALTABLETPriority Review
Approved
Jan 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRELAY (troglitazone) is an oral thiazolidinedione small-molecule approved in 1997 for type 2 diabetes management. It enhances insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ). The drug is indicated for patients with type 2 diabetes who are inadequately controlled on diet and exercise alone or as an adjunct to other antidiabetic agents.
LOE Approaching
With LOE approaching, the brand team is likely in defensive/lifecycle management mode with smaller headcount focused on generic transition planning and patient retention strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PRELAY offers limited career growth opportunities given its LOE approaching status and zero linked job openings. Roles are primarily defensive, focused on managing transition to generic competition, maintaining market share among legacy users, and supporting regulatory/safety obligations post-LOE.
Brand ManagerMedical Science Liaison
Worked on PRELAY at Daiichi Sankyo? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.